NASDAQ: EYEN | Healthcare / Biotechnology / USA |
1.58 | +0.0300 | +1.94% | Vol 341.92K | 1Y Perf -27.91% |
Oct 4th, 2023 16:00 DELAYED |
BID | 1.54 | ASK | 1.66 | ||
Open | 1.55 | Previous Close | 1.55 | ||
Pre-Market | - | After-Market | 1.66 | ||
- - | 0.08 5.06% |
Target Price | 12.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 659.49 | Finscreener Ranking | ★★★★ 52.46 | |
Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★ 38.90 | |
Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★ 38.59 | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 1.84 | Earnings Rating | Strong Buy | |
Market Cap | 60.37M | Earnings Date | 9th Nov 2023 | |
Alpha | -0.00 | Standard Deviation | 0.24 | |
Beta | 1.68 |
Today's Price Range 1.531.67 | 52W Range 1.505.85 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -8.14% | ||
1 Month | -17.28% | ||
3 Months | -36.55% | ||
6 Months | -56.71% | ||
1 Year | -27.91% | ||
3 Years | -51.53% | ||
5 Years | -59.49% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -88.41 | |||
ROE last 12 Months | -153.85 | |||
ROA (5Y Avg) | -31.12 | |||
ROA last 12 Months | -67.04 | |||
ROC (5Y Avg) | -111.61 | |||
ROC last 12 Months | -93.51 | |||
Return on invested Capital Q | -24.44 | |||
Return on invested Capital Y | 15.93 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-3.30 | ||||
3.20 | ||||
5.82 | ||||
- | ||||
-3.20 | ||||
-0.81 | ||||
3.20 | ||||
0.56 | ||||
54.85M | ||||
Forward PE | -2.07 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.70 | ||||
2.70 | ||||
0.44 | ||||
0.36 | ||||
-27.60 | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
100.00 | ||||
-182.40 | ||||
-179.40 | ||||
- | ||||
-99.25 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.20 | -0.16 | 20.00 |
Q01 2023 | -0.19 | -0.15 | 21.05 |
Q04 2022 | -0.21 | -0.17 | 19.05 |
Q03 2022 | -0.20 | -0.21 | -5.00 |
Q02 2022 | -0.18 | -0.22 | -22.22 |
Q01 2022 | - | -0.24 | - |
Q04 2021 | - | 0.10 | - |
Q03 2021 | -0.26 | -0.23 | 11.54 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.20 | 16.67 | Positive |
12/2023 QR | -0.25 | 3.85 | Positive |
12/2023 FY | -0.69 | 4.17 | Positive |
12/2024 FY | -0.80 | 3.61 | Positive |
Next Report Date | 9th Nov 2023 |
Estimated EPS Next Report | -0.20 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 341.92K |
Shares Outstanding | 38.21K |
Shares Float | 29.50M |
Trades Count | 1.70K |
Dollar Volume | 545.50K |
Avg. Volume | 205.49K |
Avg. Weekly Volume | 155.48K |
Avg. Monthly Volume | 227.30K |
Avg. Quarterly Volume | 233.69K |
Eyenovia Inc. (NASDAQ: EYEN) stock closed at 1.58 per share at the end of the most recent trading day (a 1.94% change compared to the prior day closing price) with a volume of 341.92K shares and market capitalization of 60.37M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Eyenovia Inc. CEO is Tsontcho Ianchulev.
The one-year performance of Eyenovia Inc. stock is -27.91%, while year-to-date (YTD) performance is -3.07%. EYEN stock has a five-year performance of -59.49%. Its 52-week range is between 1.5 and 5.85, which gives EYEN stock a 52-week price range ratio of 1.84%
Eyenovia Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 3.20, a price-to-sale (PS) ratio of 5.82, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -67.04%, a ROC of -93.51% and a ROE of -153.85%. The company’s profit margin is -99.25%, its EBITDA margin is -179.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Eyenovia Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Eyenovia Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for Eyenovia Inc. is Strong Buy (1), with a target price of $12, which is +659.49% compared to the current price. The earnings rating for Eyenovia Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eyenovia Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eyenovia Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.02, ATR14 : 0.10, CCI20 : -140.40, Chaikin Money Flow : -0.20, MACD : -0.09, Money Flow Index : 44.03, ROC : -10.92, RSI : 34.16, STOCH (14,3) : 10.00, STOCH RSI : 0.31, UO : 35.47, Williams %R : -90.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eyenovia Inc. in the last 12-months were: Charles E. Mather (Buy at a value of $7 470), Ianchulev Tsontcho (Sold 270 000 shares of value $1 275 000 ), Michael M. Rowe (Buy at a value of $15 400), Rowe Michael (Buy at a value of $15 400), Rowe Michael (Sold 0 shares of value $-27 200 ), Stuart M. Grant (Buy at a value of $32 630), Tsontcho Ianchulev (Sold 120 000 shares of value $480 000 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Eyenovia Inc is a clinical-stage biopharmaceutical company operating in the US. It is engaged in developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. The pipeline products of the company are MicroProst for chronic angle closure glaucoma, MicroStat for pharmacologic mydriasis, MicroTears for dry eye and MicroPine for myopia.
CEO: Tsontcho Ianchulev
Telephone: +1 917 289-1117
Address: 295 Madison Avenue, New York 10017, NY, US
Number of employees: 29
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.